Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
In a patient with hormone-positive early breast cancer who experienced a myocardial infarction (MI) while on aromatase inhibitors (AI), should tamoxifen be considered as an alternative treatment?
Related Questions
Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
How do you treat metastatic breast cancer which is HR positive, Her2 negative with PIK3CA+ and high tumor mutational burden (>10) who progressed after prior ET+CDK 4/6 and PIK3CA inhibitor therapy?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
What are your top takeaways in Breast Cancer from ASCO 2024?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you offer local therapy with either SBRT or Y-90 in a patient with metastatic ER+ HER2 low breast cancer with two oligometastatic liver lesions currently on AI + CDK4/6 inhibitor?
Is there any data to use PIK3CA directed agents in mutated metastatic triple negative breast cancer?
How would you approach a patient with metastatic high grade neuroendocrine carcinoma of the breast which is HR+ HER2 negative?
Is there any benefit of anastrozole in addition to fulvestrant and palbociclib in a patient with HR+ metastatic breast cancer?
What are your top takeaways in Breast Cancer from ASTRO 2024?
